NMRA Valuation

Neumora Therapeutics Inc

Add to Watchlist

Advanced Chart

2.680

-0.01(-0.372%)1D

NMRA Relative Valuation

NMRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NMRA is overvalued; if below, it's undervalued.

Historical Valuation

Neumora Therapeutics Inc (NMRA) is now in the Fair zone, suggesting that its current forward PS ratio of 2.86 is considered Fairly compared with the five-year average of -5.01. The fair price of Neumora Therapeutics Inc (NMRA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.77

Fair

-2.72

Trailing

Forward

-1.34

EV/EBITDA

Neumora Therapeutics Inc. (NMRA) has a current EV/EBITDA of -1.34. The 5-year average EV/EBITDA is -3.84. The thresholds are as follows: Strongly Undervalued below -10.66, Undervalued between -10.66 and -7.25, Fairly Valued between -0.43 and -7.25, Overvalued between -0.43 and 2.98, and Strongly Overvalued above 2.98. The current Forward EV/EBITDA of -1.34 falls within the Historic Trend Line -Fairly Valued range.

-1.38

EV/EBIT

Neumora Therapeutics Inc. (NMRA) has a current EV/EBIT of -1.38. The 5-year average EV/EBIT is -3.80. The thresholds are as follows: Strongly Undervalued below -10.54, Undervalued between -10.54 and -7.17, Fairly Valued between -0.43 and -7.17, Overvalued between -0.43 and 2.94, and Strongly Overvalued above 2.94. The current Forward EV/EBIT of -1.38 falls within the Historic Trend Line -Fairly Valued range.

2.69

Neumora Therapeutics Inc. (NMRA) has a current PS of 2.69. The 5-year average PS is 0.07. The thresholds are as follows: Strongly Undervalued below -0.78, Undervalued between -0.78 and -0.36, Fairly Valued between 0.49 and -0.36, Overvalued between 0.49 and 0.91, and Strongly Overvalued above 0.91. The current Forward PS of 2.69 falls within the Strongly Overvalued range.

-2.53

P/OCF

Neumora Therapeutics Inc. (NMRA) has a current P/OCF of -2.53. The 5-year average P/OCF is -6.39. The thresholds are as follows: Strongly Undervalued below -15.28, Undervalued between -15.28 and -10.83, Fairly Valued between -1.95 and -10.83, Overvalued between -1.95 and 2.49, and Strongly Overvalued above 2.49. The current Forward P/OCF of -2.53 falls within the Historic Trend Line -Fairly Valued range.

-2.88

P/FCF

Neumora Therapeutics Inc. (NMRA) has a current P/FCF of -2.88. The 5-year average P/FCF is -6.08. The thresholds are as follows: Strongly Undervalued below -14.15, Undervalued between -14.15 and -10.12, Fairly Valued between -2.04 and -10.12, Overvalued between -2.04 and 1.99, and Strongly Overvalued above 1.99. The current Forward P/FCF of -2.88 falls within the Historic Trend Line -Fairly Valued range.

Neumora Therapeutics Inc (NMRA) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 3.20 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 3.20, the current P/B ratio is about -100.00% higher. Neumora Therapeutics Inc (NMRA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -43.50%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -43.50% , the current FCF yield is about -100.00% lower.

3.30

P/B

Median3y

3.20

Median5y

3.20

-0.46

FCF Yield

Median3y

-43.50

Median5y

-43.50

Competitors Valuation Multiple

The average P/S ratio for NMRA's competitors is 6.78, providing a benchmark for relative valuation. Neumora Therapeutics Inc Corp (NMRA) exhibits a P/S ratio of 2.69, which is -60.31% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NMRA.O

Neumora Therapeutics Inc

Cullinan Therapeutics Inc

Fulcrum Therapeutics Inc

Performance Decomposition

Market capitalization of NMRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NMRA in the past 1 year is driven by Unknown.